Genes and proteins of the alternative steroid backdoor pathway for dihydrotestosterone synthesis are expressed in the human ovary and seem enhanced in the polycystic ovary syndrome

Molecular and Cellular Endocrinology

Volumn 441, Issue , 2017, Pages 116-123

  Marti, Nesa ^a,b   Galván, José A ^b   Pandey, Amit V ^a   Trippel, Mafalda ^b   Tapia, Coya ^b   Müller, Michel ^a   Perren, Aurel ^b   Flück, Christa E ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Adrenals; Androgen biosynthesis; Androgens; Classic and alternative backdoor pathway; Dihydrotestosterone; Human ovary; PCOS; Testis

Indexed keywords

ALDOSTERONE; ANDROGEN; ANDROSTANOLONE;

ADRENAL CORTEX; AKR1C2 GENE; AKR1C3 GENE; ANDROGEN SYNTHESIS; ARTICLE; CONTROLLED STUDY; GENE; GENE EXPRESSION; HORMONE SYNTHESIS; HSD3B2 GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LEYDIG CELL; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RODH GENE; SRD5A2 GENE; ZONA GLOMERULOSA; ZONA RETICULARIS; ADOLESCENT; ADRENAL GLAND; ADULT; BIOSYNTHESIS; CHILD; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; MIDDLE AGED; OVARY; TESTIS; YOUNG ADULT;

ADOLESCENT; ADRENAL GLANDS; ADULT; BIOSYNTHETIC PATHWAYS; CHILD; DIHYDROTESTOSTERONE; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; OVARY; POLYCYSTIC OVARY SYNDROME; TESTIS; YOUNG ADULT;

EID: 84979765631     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2016.07.029     Document Type: Article

References (24)

1. Auchus, R.J., The backdoor pathway to dihydrotestosterone. Trends Endocrinol. Metab. 15 (2004), 432–438.
2. Biason-Lauber, A., Miller, W.L., Pandey, A.V., Fluck, C.E., Of marsupials and men: “Backdoor” dihydrotestosterone synthesis in male sexual differentiation. Mol. Cell Endocrinol. 371 (2013), 124–132.
3. Chang, K.H., Li, R., Papari-Zareei, M., Watumull, L., Zhao, Y.D., Auchus, R.J., Sharifi, N., Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 13728–13733.
4. Fassnacht, M., Schlenz, N., Schneider, S.B., Wudy, S.A., Allolio, B., Arlt, W., Beyond adrenal and ovarian androgen generation: increased peripheral 5alpha-reductase activity in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 88 (2003), 2760–2766.
5. Fluck, C.E., Meyer-Boni, M., Pandey, A.V., Kempna, P., Miller, W.L., Schoenle, E.J., Biason-Lauber, A., Why boys will be boys: two pathways of fetal testicular androgen biosynthesis are needed for male sexual differentiation. Am. J. Hum. Genet. 89 (2011), 201–218.
6. Galván, J.A., Astudillo, A., Vallina, A., Fonseca, P.J., Gómez-Izquierdo, L., García-Carbonero, R., González, M.V., Epithelial-mesenchymal transition markers in the differential diagnosis of gastroenteropancreatic neuroendocrine tumors. Am. J. Clin. Pathol. 140 (2013), 61–72.
7. Goodarzi, M.O., Shah, N.A., Antoine, H.J., Pall, M., Guo, X., Azziz, R., Variants in the 5α-reductase type 1 and type 2 genes are associated with the polycystic ovary syndrome and the severity of hirsutism in affected women. J. Clin. Endocrinol. Metab. 91 (2006), 4085–4091.
8. 21 steroids are substrates for human cytochrome P450c17. Arch. Biochem. Biophys. 418 (2003), 151–160.
9. Homma, K., Hasegawa, T., Nagai, T., Adachi, M., Horikawa, R., Fujiwara, I., Tajima, T., Takeda, R., Fukami, M., Ogata, T., Urine steroid hormone profile analysis in cytochrome P450 oxidoreductase deficiency: implication for the backdoor pathway to dihydrotestosterone. J. Clin. Endocrinol. Metab. 91 (2006), 2643–2649.
10. Hu, Y.C., Wang, P.H., Yeh, S., Wang, R.S., Xie, C., Xu, Q., Zhou, X., Chao, H.T., Tsai, M.Y., Chang, C., Subfertility and defective folliculogenesis in female mice lacking androgen receptor. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 11209–11214.
11. Ishibashi, H., Suzuki, T., Suzuki, S., Moriya, T., Kaneko, C., Takizawa, T., Sunamori, M., Handa, M., Kondo, T., Sasano, H., Sex steroid hormone receptors in human thymoma. J. Clin. Endocrinol. Metab. 88 (2003), 2309–2317.
12. Jakimiuk, A.J., Weitsman, S.R., Magoffin, D.A., 5α-reductase activity in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 84 (1999), 2414–2418.
13. Manson, Jl, Ushijima, K., Doody, K.M., Nagai, K., Naville, D., Head, J.R., Milewich, L., Rainey, W.E., Ralph, M.M., Regulation of expression of the 3β-hydroxysteroid dehydrogenases of human placenta and fetal adrenal. J. Steroid Biochem. Mol. Biol. 47 (1993), 151–159.
14. Kamrath, C., Hochberg, Z., Hartmann, M.F., Remer, T., Wudy, S.A., Increased activation of the alternative “backdoor” pathway in patients with 21-hydroxylase deficiency; evidence from urinary steroid hormone analysis. J. Clin. Endocrinol. Metab. 97 (2012), E367–E375.
15. Keefe, C.C., Godman, M.M., Zhang, K., Clarke, N., Reitz, R.E., Welt, C.K., Simultaneous measurement of thirteen steroid hormones in women with polycystic ovary syndrome and control women using liquid chromatography-tandem mass spectrometry. PLoS One, 9, 2014, e93805.
16. Miller, W.L., Auchus, R.J., The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr. Rev. 32 (2011), 81–151.
17. Munzker, J., Hofer, D., Trummer, C., Ulbing, M., Hager, A., Pieber, T., Owen, L., Keevil, B., Brabant, G., Lerchbaum, E., Obermayer-Pietsch, B., Testosterone to dihydrotestosterone ratio as a new biomarker for an adverse metabolic phenotype in the polycystic ovary syndrome. J. Clin. Endocrinol. Metabol. 100 (2015), 653–660.
18. Nakamura, Y., Gang, H.X., Suzuki, T., Sasano, H., Rainey, W.E., Adrenal changes associated with adrenarche. Rev. Endocr. Metab. Disord. 10 (2008), 19–26.
19. Nelson, V.L., Qin, K., Rosenfield, R.L., Wood, J.R., Penning, T.M., Legro, R.S., Strauss, J.F., McAllister, J.M., The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 86 (2003), 2760–2766.
20. Penning, T.M., Burczynski, M.E., Jez, J.M., Hung, C.F., Lin, H.K., Ma, H., Moore, M., Palackal, N., Ratnam, K., Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem. J. 351 (2000), 67–77.
21. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 19 (2004), 41–47.
22. Shiina, H., Matsumoto, T., Sato, T., Igarashi, K., Miyamoto, J., Takemasa, S., Sakari, M., Takada, I., Nakamura, T., Metzger, D., Chambon, P., Kanno, J., Yoshikawa, H., Kato, S., Premature ovarian failure in androgen receptor-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 224–229.
23. Torchen, L.C., Idkowiak, J., Fogel, N.R., O'Neil, D.M., Shackleton, C.H.L., Arlt, W., Dunaif, A., Evidence for increased 5α-reductase activity during early childhood in daughters of women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 101 (2016), 2069–2075, 10.1210/jc.2015-3926.
24. Wilson, J.D., Auchus, R.J., Leihy, M.W., Guryev, O.L., Estabrook, R.W., Osborn, S.M., Shaw, g, Renfree, M.B., 5alpha-androstane-3alpha,17beta-diol is formed in tammar wallaby pouch young testes by a pathway involving 5alpha-pregnane-3alpha,17alpha-diol-20 one as a key intermediate. Endocrinology 144 (2003), 575–580.